home / stock / mkkgy / mkkgy quote
Last: | $32.735 |
---|---|
Change Percent: | -2.13% |
Open: | $33.0285 |
Close: | $32.735 |
High: | $33.0285 |
Low: | $32.6 |
Volume: | 31,218 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$32.735 | $33.0285 | $32.735 | $33.0285 | $32.6 | 31,218 | 05-03-2024 |
$32.34 | $32.21 | $32.34 | $32.34 | $31.93 | 48,814 | 05-02-2024 |
$31.63 | $31.72 | $31.63 | $32.0699 | $31.46 | 25,595 | 05-01-2024 |
$31.78 | $31.745 | $31.78 | $31.99 | $31.54 | 48,029 | 04-30-2024 |
$32.17 | $31.94 | $32.17 | $32.32 | $31.9 | 63,198 | 04-29-2024 |
$32.25 | $32.406 | $32.25 | $32.85 | $31.9 | 49,896 | 04-26-2024 |
$32.07 | $31.77 | $32.07 | $32.23 | $31.77 | 32,298 | 04-25-2024 |
$32.44 | $32.75 | $32.44 | $32.778 | $32.38 | 32,566 | 04-24-2024 |
$32.9 | $32.95 | $32.9 | $32.99 | $32.75 | 60,428 | 04-23-2024 |
$31.39 | $31.29 | $31.39 | $31.577 | $31.225 | 76,179 | 04-22-2024 |
$31.09 | $31.02 | $31.09 | $31.14 | $30.96 | 50,492 | 04-19-2024 |
$31.07 | $30.845 | $31.07 | $31.28 | $30.845 | 63,248 | 04-18-2024 |
$31.28 | $31.41 | $31.28 | $31.46 | $31.14 | 51,750 | 04-17-2024 |
$32 | $31.94 | $32 | $32.2401 | $31.94 | 72,811 | 04-16-2024 |
$32.02 | $32.5165 | $32.02 | $32.58 | $32.01 | 52,136 | 04-15-2024 |
$32.49 | $32.84 | $32.49 | $32.84 | $32.47 | 56,854 | 04-12-2024 |
$32.63 | $32.82 | $32.63 | $32.82 | $32.41 | 66,376 | 04-11-2024 |
$32.25 | $32.212 | $32.25 | $32.38 | $32.15 | 43,434 | 04-10-2024 |
$33.28 | $33.108 | $33.28 | $33.34 | $33.108 | 365,754 | 04-09-2024 |
$33 | $33.16 | $33 | $33.19 | $32.86 | 1,387,339 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Merck KGaA ADR Company Name:
MKKGY Stock Symbol:
OTCMKTS Market:
Pfizer Inc (NYSE: PFE) agreed to donate the rights of royalties from sales of cancer drug Bavencio (avelumab) to the American Associ...
Merck KGaA (OTC: MKGAF) (OTC: MKKGY) says its two Phase 3 EVOLUTION trials (evolutionRMS 1 and evolutionRMS 2) of evobruti...
Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova. Metenova is projected to generate reven...